252 related articles for article (PubMed ID: 9521174)
1. Re: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
Atkins CD
J Natl Cancer Inst; 1998 Mar; 90(6):468-9. PubMed ID: 9521174
[No Abstract] [Full Text] [Related]
2. Overview of randomized trials of systemic adjuvant therapy.
Ravdin PM
Cancer Treat Res; 2000; 103():157-81. PubMed ID: 10948446
[No Abstract] [Full Text] [Related]
3. [Endocrine therapy for postmenopausal breast cancer (role of cycline D1)].
Manikhas AG; Skvortsov VA; Manikhas GM; Raskin GA; Oganesian AS; Shemerovskiĭ AK
Vopr Onkol; 2011; 57(5):641-4. PubMed ID: 22238936
[No Abstract] [Full Text] [Related]
4. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
Colleoni M; Munzone E
Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant treatment of breast cancer.
Akerley WL
R I Med; 1995 Sep; 78(9):250-3. PubMed ID: 7579720
[No Abstract] [Full Text] [Related]
6. Equivalence between ovarian suppression and chemotherapy in the adjuvant treatment of endocrine-responsive breast cancer.
Di Leo A; Buyse M
J Clin Oncol; 2002 Apr; 20(7):1954-5. PubMed ID: 11919262
[No Abstract] [Full Text] [Related]
7. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
Tan SH; Wolff AC
Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
[TBL] [Abstract][Full Text] [Related]
8. Changing concepts of hormone receptor-positive advanced breast cancer therapy.
Chlebowski RT
Clin Breast Cancer; 2013 Jun; 13(3):159-66. PubMed ID: 23228361
[No Abstract] [Full Text] [Related]
9. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. boccardo@hp380.ist.unige.it.
Boccardo F; Rubagotti A; Amoroso D; Mesiti M; Romeo D; Sismondi P; Giai M; Genta F; Pacini P; Distante V; Bolognesi A; Aldrighetti D; Farris A
J Clin Oncol; 2000 Jul; 18(14):2718-27. PubMed ID: 10894871
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M;
J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087
[TBL] [Abstract][Full Text] [Related]
11. Is adjuvant tamoxifen recommended in post-menopausal node-negative breast cancer patients with high estrogen receptor values?
Floiras JL; Hacene K; Turpin F; Spyratos F
Int J Biol Markers; 2000; 15(2):135-8. PubMed ID: 10883886
[TBL] [Abstract][Full Text] [Related]
12. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
Fisher B; Dignam J; Wolmark N; DeCillis A; Emir B; Wickerham DL; Bryant J; Dimitrov NV; Abramson N; Atkins JN; Shibata H; Deschenes L; Margolese RG
J Natl Cancer Inst; 1997 Nov; 89(22):1673-82. PubMed ID: 9390536
[TBL] [Abstract][Full Text] [Related]
14. Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer.
Generali D; Fox SB; Berruti A; Brizzi MP; Campo L; Bonardi S; Wigfield SM; Bruzzi P; Bersiga A; Allevi G; Milani M; Aguggini S; Dogliotti L; Bottini A; Harris AL
Endocr Relat Cancer; 2006 Sep; 13(3):921-30. PubMed ID: 16954440
[TBL] [Abstract][Full Text] [Related]
15. Duration of adjuvant tamoxifen therapy.
Bryant J; Fisher B; Dignam J
J Natl Cancer Inst Monogr; 2001; (30):56-61. PubMed ID: 11773293
[TBL] [Abstract][Full Text] [Related]
16. The sequential use of endocrine treatment for advanced breast cancer: where are we?
Barrios C; Forbes JF; Jonat W; Conte P; Gradishar W; Buzdar A; Gelmon K; Gnant M; Bonneterre J; Toi M; Hudis C; Robertson JF
Ann Oncol; 2012 Jun; 23(6):1378-86. PubMed ID: 22317766
[TBL] [Abstract][Full Text] [Related]
17. Cyclin D1 expression and patient outcome after tamoxifen therapy in estrogen receptor positive metastatic breast cancer.
Han S; Park K; Bae BN; Kim KH; Kim HJ; Kim YD; Kim HY
Oncol Rep; 2003; 10(1):141-4. PubMed ID: 12469160
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant hormonal therapy for premenopausal women with breast cancer.
Brown RJ; Davidson NE
Semin Oncol; 2006 Dec; 33(6):657-63. PubMed ID: 17145345
[TBL] [Abstract][Full Text] [Related]
19. Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only?
Van Poznak CH; Hayes DF
J Natl Cancer Inst; 2006 Sep; 98(18):1261-3. PubMed ID: 16985239
[No Abstract] [Full Text] [Related]
20. MEL-18 loss mediates estrogen receptor-α downregulation and hormone independence.
Lee JY; Won HY; Park JH; Kim HY; Choi HJ; Shin DH; Kang JH; Woo JK; Oh SH; Son T; Choi JW; Kim S; Kim HY; Yi K; Jang KS; Oh YH; Kong G
J Clin Invest; 2015 May; 125(5):1801-14. PubMed ID: 25822021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
